MAP Pharmaceuticals, which is developing inhalable drugs to treat migraine and pediatric asthma, priced its 5 million share offering at $12, 20% below the midpoint of the proposed $14 to $16 range, on Thursday evening. The stock is expected to begin trading on the NASDAQ today under the ticker "MAPP." Merrill Lynch and Morgan Stanley were the joint book runners on the deal.
